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Abstract (150 words) 1 
Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; 2 
novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study 3 
regards adjuvant electrovaccination with human-CSPG4-encoded plasmid in 23 dogs with resected II/III-4 
staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-5 
positive oral cMM. Vaccination resulted in 6/12/18/24-month survival rate of respectively 6 
95.6/73.9/47.8/30.4% (MST 684 days, range 78-1694, 8/23 dogs alive) and 6/12/18/24-month DFI rate of 7 
respectively 82.6/47.8/26.1/17.4% (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 8 
6/12/18/24-month survival rate of respectively 63.2/26.3/15.8/5.3% (MST 200 days, range 75-1507, 1/19 9 
dogs alive) and 6/12/18/24-month DFI rate of respectively 52.6/26.3/10.5/5.3% (DFI 180 days, range 38-10 
1250). Overall survival and DFI of vaccinated dogs was longer in those <20 Kg. In vaccinated and non-11 
vaccinated dogs local recurrence rate was respectively 34.8% and 42% while lung metastatic rate was 12 
respectively 39% and 79%.  13 
 14 
 15 
  16 
Introduction 1 
 2 
Oral cancers account for 6-7% of all canine neoplasms whilst canine malignant melanoma (cMM) 3 
for 30-40% of all oral malignancies.
1-3 
Over 10 year-old male dogs appear to be predisposed and small 4 
dogs seem to be more affected than large dogs.
1
 CMM may be melanotic, partially melanotic and 5 
amelanotic; the latter may be misdiagnosed as undifferentiated sarcoma or as an epithelial cancer but it 6 
may be then recognized by immunohistochemistry (Melan A, PNL2).
4-7
 Oral cMM may develop 7 
everywhere in the mouth but mainly at the level of the gingiva, lips and cheek 
3
 tongue and tonsils may 8 
also be affected.
5
 At presentation oral cMM is often ulcerated, necrotic, odorous, and easily bleeding. 9 
Oral cMM are almost all malignant, with early local invasion (loss of teeth) and metastasis in up to 80% 10 
of cases.
1-3 
Metastasis to ipsilateral and contralateral regional lymph nodes (LNs) is frequent at 11 
presentation (up to 74% of cases); diagnosis should not rely on palpation only, as size may be not 12 
predictive, and cytology and histology are necessary.
8
 Metastasis at distant sites (mainly lungs) is also 13 
frequent. Reported clinical prognosticators are age, tumor size and clinical stage, bone lysis and 14 
localization (that may also influence surgical resection).
9-12
 Other prognosticators include mitotic index, 15 
percentage of atypical nuclei, Ki-67 value and PDGFR-α/-β co-expression.11, 13, 14 It has been reported that 16 
also the degree of pigmentation may have some prognostic value.
15
 Treatment of oral cMM is delivered 17 
either with a curative or palliative intent. Local control of cMM relies mainly on surgery and/or 18 
radiotherapy; then, adjuvant chemotherapy has been used in an attempt to control the systemic spread.
12, 19 
16-29 
Due to the often disappointing results obtained with standard chemotherapy and also to the high 20 
immunogenicity of malignant melanoma, immunotherapy is progressively becoming one of the most 21 
attractive adjunctive therapeutic tool, 
30-43
 also in form of combined protocols.
44
 Other treatments reported 22 
in the literature include the use of lupeol.
45-47
  23 
The goal of this paper is to report both disease-free and overall survival times following adjuvant 24 
intramuscular electrovaccination with a plasmid encoding for human (h) chondroitin sulfate proteoglycan-25 
4 (CSPG4) in prospectively enrolled client-owned dogs with en bloc surgically resected stage II and III 26 
CSPG4-positive oral cMM. Results of vaccination were compared with those obtained in a second group 27 
of dogs with stage II and III CSPG4-positive oral cMM treated with surgery alone. In previous papers, the 28 
authors have shown the expression of CSPG4 in about 57% of oral cMM
48
 and both safety and efficacy of 1 
the adjuvant anti-CSPG4 DNA vaccination in prolonging survival of treated dogs.
40
 CSPG4 is an early 2 
cell surface progression marker involved in tumor cell proliferation, migration, and invasion
49
 and has 3 
been inserted by the National Cancer Institute among the prioritized cancer antigens being worthy to be 4 
investigated in clinical trials.
50
 Since CSPG4 is a self-antigen with poor or none immunogenicity in 5 
autologous hosts, in this study we used a plasmid coding for the hCSPG4, that is characterized by 82% 6 
homology and 88% similarity in its amino-acid sequence when compared with its canine counterpart 7 
(cCSPG4), in order to break immune tolerance. The addition of electroporation to DNA vaccine delivery 8 
(electrovaccination) further increases the vaccine immunogenicity and its therapeutic efficacy, and 9 
prolongs the duration of the immune response.
51-55
   10 
 11 
Material and Methods 12 
 13 
Patient enrollment 14 
The study was conducted as a prospective bi-centric trial involving the Veterinary Teaching Hospital 15 
of the University of Turin and the Clinica Veterinaria Roma Sud of Rome. Dogs were treated according 16 
to both the Good Clinical Practice guidelines for animal clinical studies and the approval of the Ethical 17 
Committee of the University of Torino (Italy).  18 
Pretreatment work-up included physical examination, blood count, serum biochemistry, and 19 
urinalysis. Fine needle aspiration and/or biopsy were used for the preoperative tumor diagnosis. Cytology 20 
was the initial preoperative procedure adopted to clinically stage the palpable regional LNs, even in case 21 
of not apparent pathologic enlargement. A more complete staging was achieved via the surgical removal 22 
of the regional LNs at the time of the primary tumor resection and their histologic evaluation. Completion 23 
of tumor staging also included a pre-operative total body CT-scan evaluation (including skull and neck); 24 
alternatively (owners’ decision), skull and three-view chest radiographs and abdominal ultrasound 25 
examination were obtained.  26 
 Dogs without concurrent life-threatening diseases and with histologically confirmed oral stage II (2–27 
4-cm diameter, negative LN) and III (>4-cm diameter and negative LN or any tumor size with positive 28 
LN) surgically resected cMM, and with a minimum of 6 months follow-up on December 31, 2015 were 1 
included. Primary tumor en bloc resection (maxillectomy, mandibulectomy, lip/cheek excision followed 2 
by reconstruction, etc.) with the inclusion, when feasible, of at least 2 cm of macroscopically normal 3 
tissues around the tumor, and regional lymphadenectomy, were performed. Regional lymphadenectomy 4 
involved ipsilateral or bilateral mandibular nodes (single or multiple nodes) resection. For the excision 5 
margin evaluation, the cut surface was stained with a specific dye (TMD Tissue Marking Dye, Triangle 6 
Biomedical Sciences) just after surgery; the sample was then fixed in 10% formalin. The same 7 
pathologists (SI and LM) evaluated histologically all the samples and also checked for tumor or lack of 8 
tumor infiltration at the level of excision margins. Samples were also immunohistochemically tested for 9 
PNL2 (Santa Cruz Biotech, to confirm cMM diagnosis) and Ki67 expression (polyclonal Ki67 antibody 10 
A-047; DAKO; cut-off of 19.5%), mitotic index (< 4/10 hpf or > 4/hpf), and nuclear atypia (% atypical 11 
nuclei in 200 cells counted, < or >30%).
11, 13
 Immunohistochemical analysis of CSPG4 expression on 12 
cMM samples was performed as previously described.
48
 A total score ranging from 0 to 8 was assigned to 13 
each MM sample by adding the value that represented the proportion of CSPG4 positively stained tumor 14 
cells (score from 0 to 5) and the average staining intensity of CSPG4-positive tumor cells (score from 0 to 15 
3). Only dogs bearing an oral cMM with a CSPG4 score >3/8 were considered as suitable for vaccination 16 
and included in the study. Dogs were entered in the vaccination arm based on the owners’ decision; a 17 
written consent was obtained from owners before starting the vaccination. Two groups of dogs were 18 
formed: Group A involving dogs with CSPG4-positive oral cMM treated with surgery plus adjuvant anti-19 
CSPG4 DNA vaccination, and Group B involving dogs with CSPG4-positive oral cMM treated with 20 
surgery alone.  21 
 22 
Electrovaccination 23 
Vaccination started at the 3
rd
-4
th
 postoperative week and was repeated after 2 weeks and then 24 
monthly; dogs surviving over two years were then vaccinated every 6 months. Dogs were 25 
electrovaccinated with a pcDNA3.1 plasmid coding for hCSPG4 generated as previously described.
40, 56
 26 
Briefly, under a short inhalation anesthesia, the hCSPG4 plasmid (500 μg in 200 μL of 0.03% NaCl 27 
solution) was injected in dogs into the muscles of the caudal thigh. Two minutes after plasmid injection, 28 
nine electric pulses (1 high voltage, amplitude 450 V, length 50 ms, frequency 3 HZ; 1 second pause; 1 
eight low-voltage amplitude 110 V, length 20 ms, pause 300 ms) were applied to the injection site using 2 
the CLINIPORATOR (Igea, Carpi, Italy). Dogs recovered quickly from anesthesia and were standing up 3 
within 10-15 minutes from electrovaccination. They were monitored for acute, late local or systemic side 4 
effects. At each vaccination, clinical examinations, blood-work and three-view chest radiographs were 5 
performed. Sera were also collected, aliquoted, and cryopreserved at -80° C until used.  6 
 7 
CSPG4-specific antibody detection in vaccinated dog sera 8 
Sera collected before the first and after the fourth electrovaccination were analyzed for the presence 9 
of specific antibodies against hCSPG4. Sera collected at this time of treatment were used for the analysis 10 
as our previous results showed a detectable specific antibody response in all patients after the fourth 11 
electrovaccination.
40
 To specifically quantify in the serum of vaccinated dogs the antibody titer against 12 
the hCSPG4 protein an enzyme-linked immunosorbent (ELISA) assay was performed. 96-well plates 13 
(Costar®, Sigma-Aldrich) were coated in triplicate with 50 ng/well of hCSPG4 recombinant protein 14 
(R&D Systems) overnight at 4°C. Coated plates were then blocked with 10% Fetal Bovine Serum (FBS; 15 
Sigma-Aldrich) in phosphate-buffered saline (PBS; Invitrogen)-Tween (Sigma-Aldrich) 0.05% buffer for 16 
2 h at 37°C. Plates were incubated with samples diluted 1:100 in 1% blocking buffer for 1 h at 37°C. 17 
Plates were washed 3 times with a PBS-Tween buffer. The horseradish peroxidase (HRP)-conjugated 18 
anti-dog IgG antibody (AbD Serotec; 1:10.000 dilution in blocking buffer) was incubated for 1 hour at 19 
37°C. Plates were washed 6 times and chromogenic 3,30,5,50-tetramethylbenzidine substrate was added 20 
(TMB; Sigma-Aldrich). The reaction was stopped by the addition of 2N hydrochloric acid and optical 21 
density was measured at 450 nm using a microplate reader (680XR, BioRad). 22 
 23 
Immunoblot 24 
hCSPG4-positive SK-MEL-28 melanoma cells were purchased from the American Type Culture 25 
Collection and cultured in DMEM (Life Technologies) supplemented with 10% FBS. Cells were seeded 26 
at the concentration of 1.0 × 10
4
 per well in a 96-well plate in DMEM medium without serum and 27 
incubated at 37°C for 24 hours. Cells were then incubated with control CSPG4-specific mAb (0.1 mg/mL, 28 
of 149.53, 225.28, TP61.5, VF1-TP34, VF4-TP108, VF20-T87.41, VF20-VT20 mAb), with canine sera 1 
(dilution 1:20) before and after the fourth DNA vaccination or medium alone at 37°C for an additional 48 2 
hours. Cells were lysed in lysis buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, pH 7.4) containing 1% 3 
Triton X-100, and an EDTA-free protease inhibitor mix (Roche). Suspensions were extensively vortexed 4 
and incubated on ice for 15 minutes and centrifuged for 5 minutes at 13,000 rpm at 4°C. Supernatants 5 
were collected and stored at -80°C until used. Protein concentration was determined using an acid protein 6 
assay (Pierce Biotechnology). Total cell lysates were separated by sodium dodecyl sulfate–7 
polyacrylamide (SDS-PAGE) gel electrophoresis and transferred to polyvinylidene fluoride membrane of 8 
0.45-μm pore size (Millipore, Bedford, MA). After blocking the membranes with 5% nonfat dry milk 9 
with 5% BSA at 4°C ON, membranes were incubated ON at 4°C with CSPG4-specific mAb diluted 1:250 10 
in Trisbuffered saline and Tween 20 (TTBS) 3% nonfat dry milk. After washing with TTBS, HRP goat 11 
anti-mouse (1:8000 dilution) was used as secondary antibody and bound antibodies were detected using 12 
ECL Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK). 13 
 14 
Statistical analysis  15 
Non-normally distributed data are reported as median and range. Other variables are expressed as 16 
percentages. All quantitative evaluations were carried out using the Student t test. The Kaplan–Meier 17 
method was used to estimate disease-free and survival times. A Wilcoxon rank-sum test was used to 18 
compare values of the cCSPG4 expression between groups in disease outcome. Differences in survival 19 
distribution were analyzed using the log-rank test. Statistical significance was set at P < 0.05. All analyses 20 
were conducted in R.
57
  21 
 22 
Results 23 
 24 
Patient characteristics 25 
 Forty-two dogs bearing an oral cMM with a CSPG4 score > 3/8 and without any evidence of 26 
metastasis beyond the first lymphatic station (Stage II and III), were prospectively included in the study. 27 
The decision to proceed with the adjuvant vaccination was based on the owner’s consent. Among the 28 
included dogs, 29 were males (69%, 18 intact and 11 castrated) and 13 females (31%, 12 spayed and 1 1 
intact). There were 18 mixed breed dogs, 3 Golden retriever, 3 Doberman pinscher, 3 Dachshund, 3 2 
Cocker spaniel, 2 Beagle, 2 German shepherd, and 1 of each German bloodhound, dog de Bordeaux, 3 
West Highland white terrier, pinscher, dwarf schnauzer, Yorkshire, schi-tzu, and Pekingese. Mean and 4 
median age of the entire population was 11.1 and 12 years, respectively (range 4-16). Weight ranged 5 
between 2.3 and 43 kg; there were 2 dogs < 5 kg (4.8%), 9 dogs between 5-10 kg (21.4%), 12 dogs 6 
between 10-15 kg (28.6%), 8 dogs between 20-30 kg (19%), and 11 > 30 kg (26.2%).   7 
Twenty-three dogs were included in the surgery plus vaccination group (Group A), while 19 dogs 8 
received surgery alone (Group B). In Group A there were 16 males (9 castrated and 7 intact) and 7 9 
females (5 spayed and 2 intact) while in Group B there were 13 males (11 intact and 2 castrated) and 6 10 
spayed females. Mean and median age of the 23 vaccinated dogs was 11.3 and 12 years, respectively 11 
(range 6-14); mean and median age of the 19 non-vaccinated dogs was 11 and 12 years, respectively 12 
(range 4-16). Mean and median weight of the 23 vaccinated dogs was 18 and 13 Kg, respectively (range 13 
2.3-35); mean and median age of the 19 non-vaccinated dogs was 23.1 and 29 Kg, respectively (range 7-14 
43). No statistical differences regarding age or weight distribution in the two groups were observed.  15 
Diagnostic imaging for clinical staging was provided by radiographic evaluation in 4 dogs of Group 16 
A and 7 of Group B, and total body TC in 19 of Group A and 12 of Group B.  17 
In both Groups A and B either an ipsilateral or bilateral regional (mandibular) lymphadenectomy 18 
was performed. In Group A surgery consisted of: 10 segmental/horizontal and 1 bilateral rostral 19 
mandibulectomies, 3 maxillectomies, 7 en bloc excisions of lip and/or cheek followed by plastic 20 
reconstruction, 1 bilateral tonsillectomy, and 1 en bloc cMM tongue excision. In Group B surgery 21 
consisted of: 7 segmental/horizontal and 5 (4 bilateral, 1 unilateral) rostral mandibulectomies, 2 22 
maxillectomies and 5 en bloc excisions of lip and/or cheek followed by plastic reconstruction. A 23 
summary of the surgical resections performed is listed in Table 1. Histological evaluation of removed 24 
regional LNs allowed defining the final clinical staging of each cMM included in the study, reported in 25 
Table 2. Local bone invasion (determined by radiographs and/or CT) was evident preoperatively in 9 26 
cases of Group A and 7 of Group B (Table 2). Histology of the excision margin identified 4 incomplete 27 
removals in Group A and 4 in Group B (Table 2). All of the incomplete resections were at the level of the 28 
soft tissue and not bone. Clean margins exceeded 2mm in all the samples. 1 
The CSPG4 immunohistochemistry score for cMM of Group A or Group B is summarized in Table 2 
3. No significant difference in distribution was found between the two groups.  3 
 Ki67 immunohistochemistry results are summarized in Table 4. It was not available in 3 cases of 4 
Group A and in two of Group B. In Group A it was <19.5% in 1 case and >19.5% in 19 cases (mean 34%, 5 
median 30%, range 21%-74%). In Group B it was <19.5% in 3 cases and >19.5% in 14 cases (mean 6 
25.4%, median 24.6%, range 20%-50%).  7 
 Results regarding mitotic index are summarized in Table 4. It was not available in 3 cases of 8 
Group A and in 1 of Group B. In 20 cMM of Group A it was >4/10hpf (range 9-40, mean 25.7, median 9 
24). In cMM of Group B, it was <4/10hpf (=2) in 1 case while in the remaining 17 cases it was >4/10hpf 10 
(range 7-92, mean 29.8, median 25). 11 
Results regarding nuclear atypia are summarized in Table 4. It was not available in 3 cases of Group 12 
A and in 1 of Group B. In Group A it was <30% in 5 cases and >30 in 15 cases; in Group B, it was <30% 13 
in 7 cMM and >30% in 11 cases.  14 
 15 
Specific humoral response induced by hCSPG4 electrovaccination in cMM vaccinated dogs  16 
 The specific immune response induced by the xenogeneic hCSPG4 DNA vaccine was measured in 17 
sera by using a recombinant hCSPG4 ELISA assay. As in the previous study we have shown the presence 18 
of specific anti-hCSPG4 antibodies in all cMM dogs after the fourth hCSPG4-DNA vaccination,
40
 the 19 
specific humoral response was measured from sera before and after 4 immunizations. The level of 20 
antibody response, assessed spectrophotometrically to reflect the specific antibody binding to the 21 
hCSPG4 recombinant protein, was significantly higher in the post-vaccination sera than the pre-immune 22 
sera (Figure 1A), confirming the ability of xenogeneic hCSPG4 vaccination to induce specific antibodies 23 
in CSPG4-positive cMM dogs. The vaccine-induced antibody titer was not correlated to the cMM CSPG4 24 
positivity in vaccinated dogs (not shown); however, even if not statistically significant, a trend was 25 
evident in relation to body weight (BW) of dogs, being higher in dogs with BW < 20 Kg when compared 26 
with those with BW > 20 Kg (Figure 1B).    27 
Authors then investigated the effect of vaccination-induced specific antibodies on antigen expression 28 
in a hCSPG4-positive melanoma cell line (SK-MEL28). In vitro incubation of SK-MEL28 cells with 1 
canine sera after the fourth vaccination showed a differential decrease in the level of CSPG4 expression 2 
as compared to sera before immunization (Figure 1C). Incubation of SK-MEL28 cells with the medium 3 
alone or with CSPG4-specific mAb were used as controls for CSPG4 expression and modulation (Figure 4 
1C). Interpreting these results as a whole, they indicate the direct effect in vitro of specific antibodies 5 
detected in sera of vaccinated dogs in the modulation of CSPG4 expression in a CSPG4-positive human 6 
melanoma cell line. As CSPG4 is involved in the regulation of several pathways concerning growth, 7 
adhesion, and migration of tumor cells,
49
 these results suggest one of the non immunological mechanisms 8 
by which specific antibodies can affect CSPG4 function in the biology of melanoma cells, hampering 9 
tumor progression. As we previously showed the ability of vaccine-induced antibodies to bind the 10 
syngenic CSPG4 canine protein expressed on OLGA cells, a canine CSPG4-positive melanoma cell 11 
line,
40
 it can be speculated that the anti-cCSPG4 antibodies may carry out a similar action also in vivo. 12 
 13 
Clinical response to hCSPG4 electrovaccination 14 
 The median survival time (MST) and disease-free interval (DFI) results of Group A and Group B 15 
dogs are summarized in Table 5.  16 
 In the CSPG4-positive vaccinated dogs (Group A) the 6-, 12-, 18- and 24-month survival rates are 17 
95.6%, 73.9%, 47.8% and 30.4%, respectively. The 6-, 12-, 18- and 24-month DFI rates are 82.6%, 18 
47.8%, 26.1% and 17.4%, respectively. At the end of the observation period (December 31, 2015), 8 dogs 19 
of the Group A (35%) were still alive (mean 1064 days, median 1028 days, range 493-1694 days) and 15 20 
(65%) were dead, 11 because of the cMM (mean 416 days, median 385 days, range 78-684 days) and 4 21 
for unrelated causes (1 dog was submitted to euthanasia for very serious orthopedic/neurological 22 
problems at day 278 even though disease-free; 2 castrated male dogs developed a prostatic carcinoma and 23 
were submitted to euthanasia at day 447 and 1299, respectively; a fourth dog was euthanized at day 277 24 
for a perianal adenocarcinoma with metastatic sublumbar lymphadenopathy).  25 
 In the CSPG4-positive non-vaccinated dogs (Group B), the 6-, 12-, 18- and 24-month survival 26 
rates were 63.2%, 26.3%, 15.8% and 5.3%, respectively. The 6-, 12-, 18- and 24-month DFI rates were 27 
52.6%, 26.3%, 10.5% and 5.3% (1 dog, still disease-free, was lost to follow-up after 694 days), 28 
respectively. At the end of the observation period, 18 dogs of the Group B (94.7%) were dead. Sixteen 1 
died because of cMM (mean 295.1 days, median 184 days, range 75-1507 days), 2 for tumor-unrelated 2 
causes (1 for an idiopathic larynx paralysis at day 370, surgery refused by the owner, the second one for 3 
an idiopathic megaesophagus and ab ingestis pneumonia at day 367; both dogs were disease-free); the 4 
remaining dog of Group B was lost to follow after 694 days.  5 
 A summary of local recurrence (LR) and lung metastasis (LM) in the two groups is presented in 6 
Table 6. Local recurrence developed in 8 dogs of Group A (34.8%; mean 299.6 days, median 203.5 days, 7 
range 128-639 days). A second marginal or en bloc surgery was performed in 6 dogs; 5 of these 8 
ultimately died for their cMM at day 333, 374, 458, 574 and 684, respectively (4 of these with systemic 9 
metastasis); the sixth dog was operated at day 179 and it was alive at day 1400. A further dog had two 10 
excisions (one en bloc and one marginal) and it was alive at day 875; finally, the last dog had 5 marginal 11 
excisions, 2 cycles of palliative radiotherapy (October 2014: 2 fractions/week x 5 fractions, 6Gy each 12 
fraction; May 2015: 2 fractions/week x 5 fractions, 4Gy each fraction). In the latter dog metronomic 13 
chemotherapy was also started since June 2015 (cyclophosphamide, 15mg/m
2
 bid and thalidomide, 6 14 
mg/kg bid) and it was still alive at day 1040, without any evidence of systemic metastasis. In Group B, 8 15 
dogs developed a local recurrence (42%; mean 318.3 days, median 180 days, range 38-1250 days), for 7 16 
of which it was associated with distant metastatic disease (euthanasia or death at day 75, 174, 183, 220, 17 
224, 232 and 621 days) while a further dog had a recurrence at day 1250, it was operated and then 18 
irradiated but experienced a second local recurrence after about 200 days and was euthanized at day 1507. 19 
After the initial preoperative staging (8 metastatic LNs in Group A and 10 in Group B), distant metastasis, 20 
which was the cause of the death, developed in 9 dogs of Group A (39%; mean 267.2 days, median 196 21 
days, range 50-639 days) and 15 of Group B (79%; mean 164 days, median 137 days, range 38-445 days). 22 
 Kaplan–Meier curves for survival times and DFI were analyzed (Figure 2A and B). The MST in 23 
Group A is 684 days (range, 78-1694), in Group B 220 days (range, 75-1507) (ratio A/B=3.109). Group 24 
A exhibited a significantly longer MST than group B (P = 0.0005; Figure 2A). The median DFI in Group 25 
A is 477 days (range, 50-1694), in Group B 180 days (range, 38-1250) (ratio A/B=2.650). The Group A 26 
DFI was significantly longer than group B (P = 0.0174; Figure 2B).  27 
No statistically significant correlation was found between the clinical outcome of vaccinated patients 28 
and the excision margin status, percentages of Ki67 positivity, mitotic index, and nuclear atypia scores. 1 
Nevertheless, taking into account the BW of dogs and selecting 20 kg as a threshold, a differential trend 2 
in Group A was clearly evident, being the survival of dogs with BW <20 kg longer than that of those with 3 
BW >20 kg (Figure 3A). Albeit this is not completely surprising as smaller dogs tend to live longer than 4 
larger ones, however, survival of Group A dogs with BW <20 kg was significantly longer than both the 5 
entire population of Group B dogs (Figure 3B) and dogs of Group B with BW <20 kg (Figure 3C). On the 6 
contrary, the survival of Group A dogs with BW >20 Kg was not significantly different from Group B 7 
population, neither considered as a whole (Figure 3D) nor considering only dogs  >20 kg (Figure 3E). 8 
The same scenario is evident considering the DFI (Figure 4A-E), being the DFI of Group A dogs with 9 
BW <20 kg significantly longer than both the entire population of Group B dogs (Figure 4B) and dogs of 10 
Group B with BW <20 kg (Figure 4C). 11 
While the CSPG4 positivity of cMM in dogs of Group B is not correlated with the overall survival 12 
(not shown), it has a significant impact on survival of dogs of Group A. Indeed, even if not statistically 13 
significant, vaccinated dogs affected by a cMM with CSPG4 score ≥5 displayed a longer survival as 14 
compared to vaccinated dogs with CSPG4-positive cMM with score <5 (Figure 5A). Moreover, Group A 15 
dogs with a cMM CSPG4 score ≥5 exhibited a significantly longer MST when compared with both the 16 
entire Group B population (Figure 5B) or only with the non-vaccinated dogs affected by a cMM with  17 
CSPG4 score ≥5 (Figure 5C). This is not the case of Group A vaccinated dogs with a cMM with CSPG4  18 
score <5, as survival is not significantly longer when compared with the entire population of non-19 
vaccinated (Group B) dogs (Figure 5D) or when considering only Group B dogs with a cMM with 20 
CSPG4 score <5 (Figure 5E). The same situation is evident considering the DFI and CSPG4 expression 21 
(Figure 6A-E), being the DFI of Group A dogs with CSPG4 score ≥5 significantly longer when compared 22 
with both the entire Group B population (Figure 6B) or only with non-vaccinated dogs affected with a 23 
cMM of CSPG4 score ≥5 (Figure 6C).     24 
25 
Discussion 1 
Dogs with untreated oral cMM usually survive a few months.
9
 Surgery, when feasible, is important for 2 
the local control of oral cMM, especially for stage II and III tumors.
1, 12, 27, 28
 After surgery alone, a median 3 
survival time up to 352 days and a 1-year survival rate around 30% have been reported.
5, 12, 35
 An alternative 4 
to surgery is radiotherapy, alone (also for palliation) or adjuvantly, especially in case of incomplete margins; 5 
hypofractionated radiation protocols are also used.
3, 17, 18, 20, 21, 23, 29, 32
 Local control after radiation may be as 6 
high as 83-100% in up to 70% of oral cMM within some weeks and it seems better when cMM are rostral, 7 
small sized and without bone invasion, and when radiation is used in an adjuvant setting.
17, 18, 20, 21, 32
 8 
However, local recurrence may occur, even after a complete response has been reached;
17, 18, 20, 32 
in the not 9 
responding cMM, progression of the disease usually occurs.
17 
The reported 1- and 2-year survival rate after 10 
radiotherapy is 36-48% and 21%, respectively, with a median survival time ranging from 211 to 363 days.
17, 11 
18, 20, 21, 32 12 
Despite the local control of oral cMM provided by surgery and/or radiotherapy, distant metastasis 13 
represents the cause of death in up to 65-80% of dogs.
1, 2, 20
 No statistical increase of survival times was 14 
shown when dogs received also an adjuvant treatment.
12, 27
 Chemotherapy for oral cMM is often used as 15 
an adjunctive treatment to control distant metastasis. Drugs more frequently utilized are carboplatin, 16 
cisplatin (also in conjunction with piroxicam), and melphalan.
19, 22-24, 26, 27
 Platinum salts have also been 17 
used as radiosensitizers;
20, 21
 besides, cisplatin has been used intralesionally.
58
 In a more recent paper, 18 
metronomic chemotherapy has also been utilized.
27
  19 
As the role of adjuvant chemotherapy in prolonging survival of dogs bearing an oral cMM and 20 
controlling/delaying of the distant metastatic spread is uncertain, many studies have been addressed to 21 
alternative adjuvant treatments, such as new drugs 
59-61
 and immunotherapy,
3, 30, 31, 33-39, 41-43, 62 
also in form 22 
of combined protocols.
44
 23 
Several immunotherapeutic approaches have been attempted, finally leading, in USA, to the approval 24 
of a xenogeneic DNA vaccine against tyrosinase (ONCEPT, Merial), whose efficacy has been shown in 25 
cMM patients when compared with historical controls.
38, 42
 As ONCEPT efficacy has not been confirmed 26 
in two retrospective studies,
37, 63
 further studies should be warranted. In our previous paper, we showed 27 
both the safety and anti-tumor efficacy of CSPG4-immunotargeting in a group of dogs with surgically 28 
resected stage II–III CSPG4-positive oral MM.62 As the Authors of the present study never used 1 
ONCEPT as it has not been approved by the European Medicines Agency, no prospective comparison 2 
between the two vaccines was attempted. 3 
In the present study the Authors report the data of a larger cohort of oral CSPG4-positive cMM 4 
patients treated by surgery plus adjuvant electrovaccination with human-CSPG4-encoded plasmid  5 
(Group A) or treated by surgery alone (Group B), including both new enrolled dogs (coming also from a 6 
second center of vaccination) and those already considered in the previous study but updated in their 7 
follow-up. The distribution of age, sex, score of CSPG4 expression, percentage of Ki67 positivity, mitotic 8 
index, nuclear atypia, and clinical stage within the two groups was uniform. A third group of dogs 9 
previously considered in Riccardo et al.,
62
 i.e. those bearing a CSPG4-negative oral cMM, was not 10 
considered here due to the fact that it displayed an intermediate behavior and could not benefit anyway 11 
from the anti CSPG4-immunotargeting. In Riccardo et al.
62
 we showed that MST of vaccinated dogs was 12 
significantly longer when compared with the overall non-vaccinated canine population (both CSPG4-13 
positive and negative); DFI of vaccinated dogs was significantly longer than CSPG4-positive non-14 
vaccinated dogs but not CSPG4-negative non-vaccinated dogs or the entire non-vaccinated canine 15 
population; finally, both MST and DFI of CSPG4-positive non-vaccinated dogs showed no significant 16 
statistical difference in comparison with CSPG4-negative non-vaccinated dogs.  17 
The results obtained here confirm both the safety and immunogenicity of the electrovaccination with 18 
the hCSPG4 plasmid in dogs with CSPG4-positive oral cMM. The significant increase of the anti-19 
hCSPG4 antibody titer in the post-vaccination sera as compared to pre-vaccination sera of Group A dogs 20 
relates favorably with the significant prolongation of both survival times and DFI as compared to dogs of 21 
Group B, receiving surgery alone, but no direct correlation between the antibody titer and the survival 22 
was found. Regarding this, it should be emphasized that endpoints for a clinical trial involving an 23 
immunotherapeutic approach (targeted treatment) are more challenging and different from those 24 
involving the use of a specific cytotoxic drug; in the latter case, in fact, procedures to evaluate its efficacy 25 
are usually more direct and easier to be applied.
64
 Nevertheless, it is Authors’ hypothesis that the humoral 26 
anti-CSPG4 immunity has a direct beneficial effect on the clinical course of canine oral cMM. The 27 
vaccine-induced antibody titer in dogs with BW <20 Kg is higher than that observed in dogs with BW 28 
>20 Kg and, interestingly, vaccinated dogs with BW <20 Kg are those with survival and DFI significantly 1 
longer than the population of non-vaccinated dogs (Group B). This is not the case when we compare both 2 
the survival and DFI of vaccinated dogs with BW >20 Kg and the population of non-vaccinated dogs 3 
(Group B). These data suggest the importance of the level of the antibody titer induced by the vaccine and 4 
the potential fundamental role of the humoral response in prolonging both the survival time and DFI of 5 
vaccinated dogs; on the other hand, these results raise the question of scaling up doses in dogs with a high 6 
BW. Besides, also the CSPG4-positivity score of the cMM may have had an impact on the outcome. We 7 
have shown that anti-CSPG4 antibodies induced by the vaccine may act directly on the CSPG4 8 
expression on MM cells, down regulating the protein and, consequently, likely affecting the several 9 
cancer-related pathways regulated by CSPG4. Despite the fact that the degree of CSPG4 expression did 10 
not correlate with the survival of non-vaccinated dogs,
62
 vaccinated dogs with a cMM with a CSPG4-11 
positivity score higher than 5 survived longer than vaccinated dogs affected by an oral cMM with a 12 
CSPG4-positivity score lower than 5. It is likely that in the latter dogs a greater prevalence of CSPG4-13 
negative tumor clones are present, being able to escape the anti-CSPG4 immunity induced by the vaccine 14 
and, ultimately allowing the progression of the disease. Collectively, these results provide not only a 15 
mechanistic explanation for the therapeutic effect of anti-CSPG4 antibodies in the treatment of cMM, but 16 
also corroborate the role of CSPG4 in the biology of cMM cells.  17 
Clinical stage is a reported prognosticator and, apart from systemic metastasis which makes 18 
prognosis worse, the impact of regional lymphatic metastasis at presentation on survival is uncertain.  19 
One limitation here may have been that only the mandibular nodes were removed at surgery and 20 
histologically examined, with no attempt to identify other potential and/or alternative regional lymphatic 21 
stations (for example the retropharyngeal lymph nodes);
12, 65, 66
 for this important issue, further studies are 22 
warranted. Also the decision that the surgeons involved in this study adopted, i.e. not to remove 23 
systematically the mandibular nodes bilaterally, may have influenced the final clinical stage (N parameter 24 
of the TNM system). In all the cases in which a regional lymphatic spread is demonstrated, the addition of 25 
an adjuvant treatment should be advantageous.
27
  26 
Another important issue here is that in many published series of cases dealing with oral cMM, and 27 
also in this series, there are dogs that experience a long survival but it is not clear whether this reflects the 28 
efficacy of the treatment (despite the fact that a similar treatment was usually utilized also in dogs 1 
surviving for a shorter period of time) or a less aggressive tumoral behavior.
11
 It is the Authors’ opinion 2 
that these less malignant oral cMM may not be recognized clinically, being possible to identify them only 3 
by the evaluation of some already known prognostic factors such as Ki67, mitotic index and nuclear 4 
atypia.
3, 11
 Therefore, the evaluation of these prognosticators should always be included in all the studies 5 
dealing with the results of the different therapeutic approaches applied for oral cMM, in order to better 6 
interpret the final outcome. Therefore, according to a recent paper published by this group, also the 7 
PDGFR -α/-β co-expression in oral cMM should be evaluated and correlated with survival;14 so far, this 8 
parameter has not been evaluated yet in the cMM of the vaccinated dogs included in this paper and 9 
further study are warranted.  10 
Finally, it has been reported that the risk of local recurrence after surgery seems correlated to the size 11 
of the primary tumor.
27
 Local recurrence seems more likely after en bloc excision performed at the level 12 
of the upper jaw in comparison with the lower jaw (22% vs 48%).
67, 68
 Also the development of a local 13 
recurrence should represent a negative prognostic factor for survival but its real impact is not clear. In this 14 
series of cases a local recurrence developed mainly in the vaccinated dogs but it did not influence the 15 
continuation of vaccination when the recurrent tumors were properly treated (surgery +/- radiotherapy) 16 
provided that systemic metastasis were still under control, likely thanks to the vaccine; this was not the 17 
case of the non-vaccinated dogs in which the cause of the death was mainly due to systemic metastasis 18 
regardless the development of a local recurrence. Moreover, in this series of cases, in the group of 19 
vaccinated dogs (Group A), 3 patients died because of a second tumor (2 prostatic adenocarcinomas and , 20 
1 perianal adenocarcinoma with submandibular metastases), while in Group B, all dead dogs succumbed 21 
because of the cMM. It can be speculated that the prolongation of the survival in Group A dogs induced 22 
by the vaccine may have resulted in an increased risk of developing a second malignant tumor of a 23 
different histotype. 24 
In conclusion, the results presented here are encouraging and confirm the usefulness of the anti-25 
CSPG4 adjuvant vaccination in in dogs with oral cMM. However, they should be still considered 26 
cautiously as the number of dogs included is still low.  27 
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1 Table 1. Surgical MM resection in canine patients enrolled in the trial 
Type of surgery 
Overall population 
(n=42) 
Group A (n=23) Group B (n=19) 
Mandibulectomy                         
      Segmental/horizontal 
      Rostral 
23/42 (54.77)
a
 11/23 (47.83)
a
 12/19 (63.16)
a
 
17 10 7 
6 1 5 
Maxillectomy                       5/42 (11.90) 3/23 (13.04) 2/19 (10.53) 
Tonsillectomy                         1/42 (2.38) 1/23 (4.35) 0/19 (0.00) 
En bloc excision                         
      Lip/cheek 
      Tongue 
13/42 (30.95) 8/23 (34.78) 5/19 (26.31) 
12 7 5 
1 1 0 
a 
% in brackets    
 Table 2. Clinical stage and excision margin status of oral cMMs enrolled in the trial 
 
 Stage II Stage III 
Metastatic 
LNs 
Local bone 
Invasion 
Excision Margins 
 Complete Incomplete      
Overall population 
(n=42) 
15 (35.71)
a
 27 (64.29)
a
 18 (42.86)
a
 16 (38.09)
a
 34 (80.95)
a
 8 (19.05)
a
 
Group A (n=23) 9 (39.13) 14 (60.87) 8 (34.78) 9 (39.13) 19 (82.61) 4 (17.39) 
Group B (n=19) 6 (31.58) 13 (68.42) 10 (52.63) 7 (36.84) 15 (78.95) 4 (21.05) 
a 
% in brackets      
  
  
Table 3. Immunohistochemical CSPG4 score of MM from dogs included in the study 
CSPG4 score Overall population (n=42) Group A (n=23) Group B (n=19) 
3/8 6 (14.29)
a
 3 (13.04)
a
 3 (15.79)
a
 
4/8 8 (19.05) 5 (21.74) 3 (15.79) 
5/8 8 (19.05) 5 (21.74) 3 (15.79) 
6/8 3 (7.14) 2 (8.70) 1 (5.26) 
7/8 14 (33.33) 6 (26.09) 8 (42.11) 
8/8 3 (7.14) 2 (8.69) 1 (5.26) 
a 
% in brackets    
 Table 4. Histological and immunohistochemical characterization of the cMMs included in the 
study 
 Treshold Overall population Group A  Group B 
Ki67 
< 19.5 4/37
a
 (10.81)
b
 1/20
a
 (5.00)
b
 3/17
a
 (17.65)
b
 
> 19.5 33/37 (89.19) 19/20 (95.00) 14/17 (82.35) 
Mitotic Index 
(MI) 
< 4/10 hpf 1/38
a
 (2.63)
b
 0/20
a
 (0.00)
b
 1/18
a
 (5.56)
b
 
> 4/10 hpf 37/38 (97.37) 
20/20 
(100.00) 
17/18 (94.44) 
Nuclear 
Atypia 
(PLEOM) 
< 30% 12/38 (31.58) 5/20 (25.00) 7/18 (38.89) 
> 30% 26/38 (68.42) 15/20 (75.00) 11/18 (61.11) 
a
 number of patients for which the data were available 
b
 % in brackets 
 Table 5. Median survival time (MST) and disease-free interval (DFI) calculated at December 31, 2015 
 
Groups 
 
MST 
(days) 
 
DFI (days) 
MST (months)  DFI (months) 
  6   12 
 
  18   24     6    12     18    24 
Group A 684 
(458-∞)a 
477 
(207-∞) 
95.6% 73.9% 47.8% 30.4% 82.6% 47.8% 26.1% 17.4% 
Group B 220 
(174-∞) 
180 
(131-∞) 
63.2% 26.3% 15.8% 5.3% 52.6% 26.3% 10.5% 5.3% 
a
(LCL95%-UCL95%) Lower-Upper Control Limits 
  
 
 
 
 
 
 
 
  
Table 6. Percentage of local recurrence (LR) and lung 
metastasis (LM) for each group, calculated up to 
December 31, 2015 
Groups LR LM 
Group A (n=23) 34.80% 39.00% 
Group B (n=19) 42.00% 79.00% 
Captions to figures (separate page) 
 
Figure 1. Vaccination-induced anti-hCSPG4 humoral response in sera of cMM dogs. (A) Detection of 
hCSPG4 antibodies in sera collected before (white bar) and after the fourth DNA vaccination (black bar) 
by ELISA. Results are expressed as the mean OD at 450 nm + SD values of all vaccinated dogs. ***, 
p<0.0001, Student’s t-test. (B) Evaluation of hCSPG4 antibody response in sera collected from 
vaccinated dogs in relation to BW. Results are shown as fold change values expressing the ratio between 
post-vaccination OD/pre-vaccination OD values measured by ELISA. (C) Assessment of the effect of 
vaccine-induced anti-hCSPG4 antibodies on hCSPG4 expression. hCSPG4-positive SK-MEL28 cells 
were incubated with medium alone, CSPG4-specific mAb or canine sera before and after the fourth 
immunization at 37°c for 48 hours. Representative immunoblot analysis of CSPG4 modulation induced 
by the sera of 2 vaccinated dogs (#5 and #3) and the corresponding percentage of CSPG4 reduction 
compared to the medium is shown. Actin was used as loading control. 
Figure 2. Kaplan–Meier curves comparing survival and DFI in the two groups. (A) Survival (in days) of 
CSPG4-positive MM, vaccinated dogs (Group A, black line) and of CSPG4-positive MM, non-vaccinated 
dogs (Group B, gray dotted line; *** log-rank test p=0.0005). (B) DFI (in days) of CSPG4-positive MM, 
vaccinated dogs (Group A, black line) and of CSPG4-positive MM, non-vaccinated dogs (Group B, gray 
dotted line; * log-rank test p= 0.0174). 
Figure 3. Kaplan–Meier curves comparing survival (in days) in relation to BW of dogs. (A) Survival of 
CSPG4-positive cMM, vaccinated dogs (Group A) with BW<20 Kg (black line) and with BW>20 Kg 
(black dotted line). (B,C) Survival of CSPG4-positive cMM, vaccinated dogs (Group A) with BW<20 Kg 
(black line) in comparison with survival of (B) the entire population of non-vaccinated dogs (Group B, 
grey dotted line; ** log-rank test p= 0.0015) or of (C) non-vaccinated dogs with BW<20 Kg (Group B, 
grey line; *** log-rank test p=0.0002). (D,E) Survival of CSPG4-positive cMM vaccinated dogs (Group 
A) with BW>20 Kg (black dotted line) in comparison with survival of (D) the entire population of non-
vaccinated dogs (Group B, grey dotted line) or of (E) non-vaccinated dogs with BW>20 Kg (Group B, 
grey line). 
Figure 4. Kaplan–Meier curves comparing DFI (in days) in relation to BW of dogs. (A) DFI of CSPG4-
positive cMM vaccinated dogs (Group A) with BW<20 Kg (black line) and with BW>20 Kg (black 
dotted line). (B,C) DFI of CSPG4-positive cMM vaccinated dogs (Group A) with BW<20 Kg (black line) 
in comparison with DFI of (B) the entire population of non-vaccinated dogs (Group B, grey dotted line; * 
log-rank test p= 0.0252) or of (C) non-vaccinated dogs with BW<20 Kg (Group B, grey line; ** log-rank 
test p=0.0070). (D,E) DFI of CSPG4-positive cMM vaccinated dogs (Group A) with BW>20 Kg (black 
dotted line) in comparison with DFI of (D) the entire population of non-vaccinated dogs (Group B, grey 
dotted line) or of (E) non-vaccinated dogs with BW>20 Kg (Group B, grey line). 
Figure 5. Kaplan–Meier curves comparing survival (in days) of dogs in relation to CSPG4-positivity 
score of cMM. (A) Survival of vaccinated dogs (Group A) bearing a cMM with CSPG4-positivity score 
≥5 (black line) or <5 (black dotted line). (B,C) Survival of vaccinated dogs (Group A) bearing a cMM 
with CSPG4-positivity score ≥5 (black line) in comparison with the survival of (B) the entire population 
of non-vaccinated dogs (Group B, grey dotted line; *** log-rank test p= 0.0004) or of (C) non-vaccinated 
dogs bearing a cMM with CSPG4-positivity score ≥5 (Group B, grey line; *** log-rank test p= 0.0006). 
(D,E) Survival of vaccinated dogs (Group A) bearing a cMM with CSPG4-positivity score <5 (black 
dotted line) in comparison with the survival of (D) the entire population of non-vaccinated dogs (Group 
B, grey dotted line) or of (E) non-vaccinated dogs bearing a cMM with CSPG4-positivity score <5 
(Group B, grey line). 
Figure 6. Kaplan–Meier curves comparing DFI (in days) of dogs in relation to cMM CSPG4-positivity 
score. (A) DFI of vaccinated dogs (Group A) bearing a cMM with CSPG4-positivity score ≥5 (black line) 
or <5 (black dotted line). (B,C) DFI of vaccinated dogs (Group A) bearing a cMM with CSPG4-positivity 
score ≥5 (black line) in comparison with DFI of (B) the entire population of non-vaccinated dogs (Group 
B, grey dotted line; * log-rank test p= 0.0167) or of (C) non-vaccinated dogs bearing a cMM with 
CSPG4-positivity score ≥5 (Group B, grey line; * log-rank test p= 0.0249). (D,E) DFI of vaccinated dogs 
(Group A) bearing a cMM with CSPG4-positivity score <5 (black dotted line) in comparison with DFI of 
(D) the entire population of non-vaccinated dogs (Group B, grey dotted line) or of (E) non-vaccinated 
dogs bearing a cMM with CSPG4-positivity score <5 (Group B, grey line). 
